Advertising to Drive MannKind (MNKD) Afrezza Awareness and Adoption in Q3, Jefferies Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
MannKind (MNKD) Gains Amid Ongoing Talk of Short Squeeze
June 8, 2015 9:51 AM EDTMannKind (NASDAQ: MNKD) advanced over 5% Monday, extending recent gains amid ongoing talk of a squeeze in the heavily shorted name.
113 million shares of the stock were held short as of May 15, or about 42% of the float. Days to cover was 14.5 on average volume of 7.8 million.
... MoreMannKind (MNKD) Ticks Higher Despite Reports Affreza Difficult to Obtain
June 3, 2015 1:42 PM EDTMannKind (NASDAQ: MNKD) shares gained Wednesday, rising over 5%. Earlier its inhaled insulin drug Afrezza was featured in an article in the LA Times that discussed difficulties diabetes are having getting the drug due to doctor reluctance to prescribe it, as well as issues... More
